Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CTX-131 by CRISPR Therapeutics for Follicular Lymphoma: Likelihood of Approval
CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
CTX-131 by CRISPR Therapeutics for Mantle Cell Lymphoma: Likelihood of Approval
CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
CTX-131 by CRISPR Therapeutics for T-Cell Lymphomas: Likelihood of Approval
CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics's CTX-131?
CTX-131 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Cervical Cancer;Endometrial Cancer....
Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics's CTX-131?
CTX-131 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Metastatic Renal Cell...